ERBB2 and non-small cell lung carcinoma: The antibody–drug conjugate trastuzumab–deruxtecan (T-Dxd) conferred a response rate of 55% in heavily pretreated patients in the Destiny-Lung01 trial and is the only FDA-approved targeted anti-HER2 therapy for HER2-mutated NSCLC [21].